US 11,932,702 B2
Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptor
Daniel Janssen, Mortsel (BE); Carlo Boutton, Wielsbeke (BE); Evelyne Dombrecht, Zwijnaarde (BE); Bram Laukens, Zwijnaarde (BE); Paolo Meoni, Zwijnaarde (BE); Lily Pao, Bridgewater, NJ (US); Jan Pype, Herne (BE); Peter Schotte, De Pinte (BE); Benedikte Serruys, Sint-Michiels (BE); Ana Paula Vintem, Zwijnaarde (BE); and Diane Van Hoorick, Laarne (BE)
Assigned to Ablynx N.V., Zwijnaarde (BE); and Sanofi, Paris (FR)
Filed by Ablynx N.V., Zwijnaarde (BE); and Sanofi, Paris (FR)
Filed on Dec. 17, 2021, as Appl. No. 17/553,908.
Claims priority of provisional application 63/127,224, filed on Dec. 18, 2020.
Claims priority of application No. 20306633 (EP), filed on Dec. 21, 2020.
Prior Publication US 2022/0213215 A1, Jul. 7, 2022
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/303 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)] 28 Claims
 
1. A polypeptide that comprises at least three immunoglobulin single variable domains (ISVDs), wherein each of said ISVDs comprises three complementarity determining regions (CDRs), CDR1 to CDR3, respectively, and wherein:
a) a first ISVD specifically binds to the constant domain of a T cell receptor (TCR) on a T cell and comprises:
i. a CDR1 comprising the amino acid sequence of SEQ ID NO: 6;
ii. a CDR2 comprising the amino acid sequence of SEQ ID NO: 10; and
iii. a CDR3 comprising the amino acid sequence of SEQ ID NO: 14;
b) a second ISVD specifically binds to Glypican-3 (GPC3) and comprises:
iv. a CDR1 comprising the amino acid sequence of SEQ ID NO: 7;
v. a CDR2 comprising the amino acid sequence of SEQ ID NO: 11; and
vi. a CDR3 comprising the amino acid sequence of SEQ ID NO: 15; and
c) a third ISVD specifically binds to GPC3 and comprises:
vii. a CDR1 comprising the amino acid sequence of SEQ ID NO: 8;
viii. a CDR2 comprising the amino acid sequence of SEQ ID NO: 12; and
ix. a CDR3 comprising the amino acid sequence of SEQ ID NO: 16,
wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.